|
May 1
|
4D Molecular Therapeutics, Inc. (FDMT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
|
|
May 1
|
4DMT Announces Presentations at ARVO 2024 Annual Meeting
|
|
Apr 4
|
4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares
|
|
Mar 29
|
4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares
|
|
Mar 28
|
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
|
|
Mar 4
|
4DMT to Participate in Upcoming Investor Conferences
|
|
Feb 12
|
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
|
|
Feb 12
|
Institutional investors in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) lost 11% last week but have reaped the benefits of longer-term growth
|
|
Feb 8
|
Chief Medical Officer Robert Kim Sells Shares of 4D Molecular Therapeutics Inc
|
|
Feb 7
|
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
|
|
Feb 5
|
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
|
|
Jan 26
|
4D Molecular Therapeutics Inc CEO David Kirn Sells 5,696 Shares
|
|
Jan 23
|
4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease
|
|
Jan 19
|
All You Need to Know About 4D Molecular Therapeutics, Inc. (FDMT) Rating Upgrade to Strong Buy
|
|
Jan 9
|
4D Molecular Therapeutics Inc CEO David Kirn Sells 102,303 Shares
|
|
Jan 6
|
Andreas Halvorsen Adjusts Position in 4D Molecular Therapeutics Inc
|
|
Jan 4
|
4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates
|
|
Jan 3
|
4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases
|
|
Dec 21
|
4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD
|
|
Dec 4
|
4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference
|